RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update
04 Maio 2023 - 7:50AM
RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a
specialty pharmaceutical company focused on the commercialization
of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%,
today announced that the Company will release its first quarter
2023 financial results and provide a commercial update on Thursday,
May 11, 2023, before U.S. financial markets open.
Brian Markison, Chief Executive Officer, James
“JD” Schaub, Chief Operating Officer, and Mike DePetris, Principal
Accounting Officer, will host a conference call as follows:
Date |
Thursday, May
11, 2023 |
Time |
8:30 a.m. ET |
Toll free (U.S.) |
800-579-2543 |
International |
785-424-1789 |
|
|
Webcast (live and replay) |
ir.rvlpharma.com under the “Investors & News” section |
IMPORTANT SAFETY
INFORMATION
INDICATION
UPNEEQ® (oxymetazoline hydrochloride ophthalmic
solution), 0.1% is indicated for the treatment of acquired
blepharoptosis in adults.
WARNINGS AND PRECAUTIONS
- Ptosis may be
associated with neurologic or orbital diseases such as stroke
and/or cerebral aneurysm, Horner syndrome, myasthenia gravis,
external ophthalmoplegia, orbital infection and orbital masses.
Consideration should be given to these conditions in the presence
of ptosis with decreased levator muscle function and/or other
neurologic signs.
-
Alpha-adrenergic agonists as a class may impact blood pressure.
Advise UPNEEQ patients with cardiovascular disease, orthostatic
hypotension, and/or uncontrolled hypertension or hypotension to
seek medical care if their condition worsens.
- Use UPNEEQ with
caution in patients with cerebral or coronary insufficiency or
Sjögren’s syndrome. Advise patients to seek medical care if signs
and symptoms of potentiation of vascular insufficiency
develop.
- UPNEEQ may
increase the risk of angle closure glaucoma in patients with
untreated narrow-angle glaucoma. Advise patients to seek immediate
medical care if signs and symptoms of acute narrow-angle glaucoma
develop.
- Patients should
not touch the tip of the single patient-use container to their eye
or to any surface, in order to avoid eye injury or contamination of
the solution.
ADVERSE REACTIONS
Adverse reactions that occurred in 1-5% of
subjects treated with UPNEEQ were punctate keratitis, conjunctival
hyperemia, dry eye, blurred vision, instillation site pain, eye
irritation and headache.DRUG INTERACTIONS
-
Alpha-adrenergic agonists, as a class, may impact blood pressure.
Caution in using drugs such as betablockers, anti-hypertensives,
and/or cardiac glycosides is advised. Caution should also be
exercised in patients receiving alpha adrenergic receptor
antagonists such as in the treatment of cardiovascular disease, or
benign prostatic hypertrophy.
- Caution is
advised in patients taking monoamine oxidase inhibitors which can
affect the metabolism and uptake of circulating amines.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty
pharmaceutical company focused on the commercialization of UPNEEQ®
(oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the
treatment of acquired blepharoptosis, or low-lying eyelid, in
adults. UPNEEQ is the first non-surgical treatment option approved
by the FDA for acquired blepharoptosis.
Investor and Media Relations for RVL Pharmaceuticals
plc
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
RVL Pharmaceuticals (NASDAQ:RVLP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
RVL Pharmaceuticals (NASDAQ:RVLP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024